Small-cap biotech IPOs gaining traction amid volatility
Key Questions
What drove the resurgence in Q1 biotech IPOs?
Q1 biotech IPOs raised $1.7B, fueled by the JOBS and INVEST Acts. This marks a notable resurgence in small-cap biotech IPOs amid market volatility.
How has RTW Biotech Opportunities performed since its IPO?
RTW Biotech Opportunities reported a 136% NAV return since IPO. This outperforms the Russell 2000 Biotech Index (55%), NASDAQ Biotech Index (69%), and broader market (29%).
Why is International Biotechnology Trust bullish on biotech M&A?
IBT anticipates frenetic M&A activity following Neurocrine's $2.9B acquisition of Soleno, the fourth major deal in 2026. They view this as part of a broader wave in biotech.
Which biotech stocks have seen significant gains recently?
Aktis surged +50%, APGE +20%, while Eikon, Serina, SLS, FPS, and ELAB each rose over +100%. These movements highlight traction in small-cap biotechs.
What are some recent biotech filings and preparations?
Harpoon filed for IPO, Kailera filed for obesity drug, Grifols is prepping, and Generate raised $400M. Investors should monitor these developments closely.
What funding did Stipple Bio secure?
Stipple Bio raised $100M in funding. This is part of broader investment activity in biotech, including Sidewinder's $137M for bispecific ADCs.
What actions have LBRX and ONCY taken recently?
LB Pharmaceuticals (LBRX) registered 4.78M shares for resale via S-1 filing. Oncolytics Biotech (ONCY) established a $75M ATM offering.
What should investors watch in the biotech sector?
Key areas include lockups, clinical readouts, and M&A activity. Notable mentions are WHOOP's >$10B valuation with $1.1B bookings and Merck-Terns deal boosting XBI +36%.
Q1 biotech IPOs $1.7B + resurgence (JOBS/INVEST Acts); RTW 136% NAV; IBT bullish frenetic M&A (Soleno $2.9B Neurocrine 4th 2026 deal); Kailera obesity filing; Generate $400M; Grifols prep; APGE +20%; Harpoon filing; Aktis +50%; Eikon/Serina/SLS/FPS/ELAB +100%; WHOOP >$10B/$1.1B bookings; Merck-Terns +XBI+36%; LBRX resale; ONCY ATM; Stipple $100M. Watch lockups/readouts/M&A.